Literature DB >> 15140857

Pharmacokinetics of valaciclovir.

Conan MacDougall1, B Joseph Guglielmo.   

Abstract

While active against Herpesviridae, oral aciclovir is limited by low and inconsistent bioavailability. Modification of aciclovir by valine esterification, producing valaciclovir, results in significant increases in systemic aciclovir plasma levels. The exact mechanism of increased absorption with valaciclovir is not fully determined but probably involves intestinal dipeptide transporters, followed by rapid ester hydrolysis in the small intestine and liver. The enhanced pharmacokinetics of valaciclovir have translated into improvements in clinical efficacy and patient convenience.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140857     DOI: 10.1093/jac/dkh244

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Authors:  Michael B Bolger; Viera Lukacova; Walter S Woltosz
Journal:  AAPS J       Date:  2009-05-12       Impact factor: 4.009

2.  [Therapy refractory stromal Herpes keratitis under aciclovir].

Authors:  C Spira; N Szentmáry; A Hasenfus; M Sauter; S Smola; B Seitz
Journal:  Ophthalmologe       Date:  2014       Impact factor: 1.059

Review 3.  Update on Herpes simplex keratitis management.

Authors:  Daniel Sibley; Daniel F P Larkin
Journal:  Eye (Lond)       Date:  2020-08-25       Impact factor: 3.775

4.  Left out but not forgotten: Should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV?

Authors:  Darrell H S Tan; Rupert Kaul; Sharon Walsmley
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

5.  Valacyclovir as Initial Treatment for Acute Retinal Necrosis: A Pharmacokinetic Modeling and Simulation Study.

Authors:  Tao Liu; Aabha Jain; Michael Fung; Christopher Vinnard; Vijay Ivaturi
Journal:  Curr Eye Res       Date:  2017-03-30       Impact factor: 2.424

Review 6.  The role of human carboxylesterases in drug metabolism: have we overlooked their importance?

Authors:  S Casey Laizure; Vanessa Herring; Zheyi Hu; Kevin Witbrodt; Robert B Parker
Journal:  Pharmacotherapy       Date:  2013-02       Impact factor: 4.705

7.  Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.

Authors:  Roni Scherzer-Attali; Riccardo Pellarin; Marino Convertino; Anat Frydman-Marom; Nirit Egoz-Matia; Sivan Peled; Michal Levy-Sakin; Deborah E Shalev; Amedeo Caflisch; Ehud Gazit; Daniel Segal
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

8.  Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens.

Authors:  S Abdalla; C Briand; M Oualha; M Bendavid; A Béranger; S Benaboud; J-M Tréluyer; Y Zheng; C Capito; Z Demir; F Foissac; S Winter; I Gana; S Boujaafar; N Bouazza; D Hirt
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

9.  β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.

Authors:  Chandrav De; Dongmei Liu; Bo Zheng; Uma S Singh; Satish Chavre; Catherine White; Robert D Arnold; Fred K Hagen; Chung K Chu; Jennifer F Moffat
Journal:  Antiviral Res       Date:  2014-07-19       Impact factor: 5.970

10.  Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.

Authors:  Jeffrey Blumer; Adib Rodriguez; Pablo J Sánchez; William Sallas; Guenther Kaiser; Kamal Hamed
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.